Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/116248
Title: Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study
Authors: Sartore, Giovanni 
Chilelli, Nino Cristiano 
Seraglia, Roberta
Ragazzi, Eugenio 
Marin, Raffaella 
Roverso, Marco 
Cosma, Chiara 
Vaccaro, Olga
Burlina, Silvia 
Lapolla, Annunziata 
Keywords: Clinical trials;Diabetes;Lipoproteins;Mass spectrometry;Oxidized lipids
Keywords Plus: HIGH-DENSITY-LIPOPROTEIN;END-PRODUCTS;CHOLESTEROL;HYPERGLYCEMIA;GLYCATION;METFORMIN;MELLITUS;OVERWEIGHT;STRESS;EFFLUX
Mesh headings: Diabetes Mellitus, Type 2;Hypoglycemic Agents;Lipoproteins;Pioglitazone;Sulfonylurea Compounds
Secondary Mesh headings: Aged;Apolipoprotein A-I;Blood Glucose;Cholesterol, HDL;Female;Glycation End Products, Advanced;Humans;Lipids;Lipoproteins, HDL;Lipoproteins, LDL;Male;Middle Aged;Oxidation-Reduction;Thiazolidinediones
Issue Date: May-2019
Publisher: SPRINGER-VERLAG ITALIA SRL
Journal: Acta diabetologica 
Abstract: 
Type 2 diabetes (DM2) is associated to oxidative modifications of high-density lipoproteins (HDL), which can interfere with their function. Pioglitazone has proved effective in raising HDL cholesterol (HDL-C) and lowering small dense low-density lipoprotein (LDL), but no clinical studies have examined its effect on lipoprotein oxidation in patients with DM2.
URI: http://hdl.handle.net/20.500.12857/116248
ISSN: 09405429
DOI: 10.1007/s00592-018-01278-2
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

1
Last Week
0
Last month
0
checked on Jul 15, 2021

SCOPUSTM   
Citations

1
checked on Sep 1, 2020

WEB OF SCIENCETM
Citations

3
checked on Nov 26, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.